Corcept TherapeuticsCORT
Market Cap: $4.4B
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Employees: 352
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
31% more call options, than puts
Call options by funds: $47.4M | Put options by funds: $36.1M
22% more capital invested
Capital invested by funds: $2.37B [Q1] → $2.9B (+$525M) [Q2]
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
1% more funds holding
Funds holding: 282 [Q1] → 284 (+2) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
9% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 113
5.35% less ownership
Funds ownership: 91.08% [Q1] → 85.74% (-5.35%) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Piper Sandler David Amsellem 65% 1-year accuracy 24 / 37 met price target | 59%upside $67 | Overweight Maintained | 18 Sept 2024 |
Canaccord Genuity Edward Nash 53% 1-year accuracy 9 / 17 met price target | 85%upside $78 | Buy Maintained | 31 Jul 2024 |
Canaccord Genuity Edward Nash 53% 1-year accuracy 9 / 17 met price target | 10%downside $38 | Buy Maintained | 30 Jul 2024 |
Piper Sandler David Amsellem 65% 1-year accuracy 24 / 37 met price target | 10%downside $38 | Overweight Maintained | 30 Jul 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 42 / 136 met price target | 7%upside $45 | Buy Maintained | 30 Jul 2024 |
Financial journalist opinion
Based on 6 articles about CORT published over the past 30 days